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Abstract The aim of this qualitative study was to
examine the experience of individuals facing a choice
about genetic counselling/testing in the context of newly
diagnosed colorectal cancer (CRC). Nineteen individuals
with newly diagnosed CRC, including 12 individuals who
accepted genetic counselling (‘‘acceptors’’) and 7 individ-
uals who declined genetic counselling (‘‘refusers’’), were
interviewed using a standardized questionnaire guide
which focused on motivations and barriers experienced in
the decision process. Data were analyzed using Karlsson’s
Empirical Phenomenological method of data analysis
(Karlsson in Psychological qualitative research from a
phenomenological perspective. Almgvist and Wiksell
International, Stockholm, 1993). Three major themes were
identified: facing challenges in health literacy; mapping an
unknown territory; and adjusting to cancer. The study
participants’ testimonies provided novel insights into
potential reasons for patient non-engagement in pilot
studies of reflex testing for Lynch syndrome, and allowed
us to formulate several recommendations for enhancing
patient engagement. Our study findings suggest that patient
engagement in clinical cancer genetics services, including
reflex testing for Lynch syndrome, can only be achieved by
addressing current health literacy issues, by deconstructing
current misconceptions related to potential abuses of
genetic information, by emphasizing the clinical utility of
genetic assessment, and by adapting genetics practices to
the specific context of cancer care.
Keywords Colorectal cancer  Lynch syndrome 
Genetic counselling  Patient engagement  Universal
screening  Health literacy
Introduction
Despite advances in our understanding of hereditary forms
of colorectal cancer (CRC), the identification of individuals
at high risk due to an inherited predisposition remains a
significant clinical and public health challenge. The
majority of individuals at high risk remain unidentified and
uniformed about prevention and management strategies.
Factors affecting the uptake of clinical genetic services
by individuals with suspected hereditary predisposition to
CRC have included patient, health professional, and system
variables [1]. Poor awareness of genetic testing for CRC
predisposition has been identified among primary care
physicians, gastroenterologists and oncologists [2–4]. Even
in the setting of a well established North American gas-
troenterology cancer clinic, only a minority (17 %) of CRC
patients eligible for genetic assessment were actually
referred [4]. In the province of Ontario, only 28.3 % of
Lynch syndrome (LS) cases identified in a provincial
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registry had been assessed by a clinical genetics service
[5]. Similar data pertaining to under-recognition and under-
referral have been reported in several American and
European settings [6–8].
The existing literature has reported several patient factors
associated with uptake of genetic counselling and testing for
inherited cancer susceptibility [9]. In general, psychological
factors have been identified to be more important determi-
nants than socio demographic variables [9–14].
Most studies carried out to assess the uptake, motiva-
tions, and barriers to genetic testing for LS have been
carried out in individuals already in the process of genetic
testing [15] or in family members of individuals known to
carry a LS mutation [11, 12, 14, 16]. There are few pub-
lished reports of the experience of genetic counselling and
testing in individuals recently diagnosed with CRC in
whom a hereditary predisposition is suspected [17–19].
Despite the paucity of evidence concerning the accept-
ability of genetic testing in newly diagnosed CRC patients,
experts recommend such testing in newly diagnosed CRC
patients to reduce morbidity and mortality in relatives, and
the implementation of universal screening for LS has been
adopted as a 2020 developmental objective by the Office of
Public Health Genomics in the United States [20, 21].
Reflex testing of colorectal tumours, defined as the
routine screening of tumours for evidence of defective
DNA mismatch repair as a phenotypic marker of LS, has
been proposed as a strategy to increase identification of
individuals with LS, and represents an emerging standard
of care [22, 23]. Two cost effectiveness analyses of reflex
testing in newly diagnosed CRC patients and a similar
analysis in newly diagnosed endometrial cancer patients
have demonstrated that cost effectiveness of such screening
is comparable to accepted screening activities in the gen-
eral population [24–26]. For several reasons, widespread
adoption of reflex testing has proven to be a challenge in
individual clinical centres, as well as in public health ini-
tiatives [27, 28]. One of the barriers identified in both the
initial clinical experience and in a recent survey of US sites
has been low uptake of genetic services by patients [22,
28]. In the initial Ohio State University experience, only
26.5 % of individuals with CRC identified to be appro-
priate for genetic assessment presented for counselling
[28]. This same group reported that only 28 % of patients
with endometrial cancer who would have been expected to
benefit from genetic counselling were actually seen by a
genetic counsellor [29]. From these data, it is clear that
patient non-engagement represents a significant barrier to
the potential effectiveness of reflex testing and that a more
complete understanding of patient barriers to the uptake of
clinical genetics services is required.
This study was designed to investigate the different
factors affecting uptake of genetic counselling and testing
in newly diagnosed CRC patients being seen in a Canadian
academic hospital Cancer Assessment Clinic. The aim of
this qualitative study was to examine the experience of
individuals facing a choice about genetic counselling/test-
ing in the context of newly diagnosed CRC, focusing on
motivations and barriers encountered. A qualitative design
allowed all aspects of the patient experience to emerge in
the data. Although our study was carried out prior to the
introduction of reflex testing, our findings have direct rel-
evance for the identification of strategies to enhance patient
engagement in clinical genetic services following an
abnormal tumour screen in the context of reflex testing.
Methods
Study design
Since the focus of the present research was on the signif-
icance research participants ascribed to genetic counselling
and testing, a qualitative methodology was chosen. This
choice facilitates a holistic, inductive and naturalistic
understanding of participants’ experiences. The Children’s
Hospital of Eastern Ontario and the Ottawa Hospital
Research Ethics Boards approved the study protocol.
Participant selection and recruitment
Eligible participants were derived from the cohort of all
newly diagnosed CRC patients (n = 332) presenting for an
initial consultation at the Ottawa Hospital Cancer Assess-
ment Clinic during the 9 month period of March through
December 2010. Eligible patients were part of a risk
assessment pilot study which addressed the role of an
advanced practice nurse in identifying individuals appro-
priate for referral for genetics assessment. In this pilot
study, 56/332 patients were identified to be high risk and
eligible for genetic counselling. Forty-five patients were
referred to Genetics and 32 were actually seen for coun-
selling [30]. Eligible participants met Ontario provincial
criteria for referral for Cancer Genetics Services [31].
Each participant was individually interviewed by the
first (ET) or third author (NMPS) and asked to describe his/
her experience of making a decision regarding genetic
counselling using a written question guide. Interviews were
audio-taped and later transcribed. Participants deemed
unable to tolerate the interview or give informed consent
were excluded.
Nineteen individuals from different families were recrui-
ted. Twelve of these individuals accepted to undergo genetic
counselling (acceptors) and seven did not (refusers) (Table 1).
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Data analysis
The Empirical Phenomenological Psychological data
analysis proposed by Karlsson [32] was used in this study.
The process of analysis was divided into many stages. In
these stages, the researcher aims to reach the highest level
of abstraction possible to draw out the essential elements of
the experience as perceived by participants. To enhance
trustworthiness, the analysis was done by the three first
authors using the consensual approach as described by
Samson and Zerter [33].
Results
Three main themes were identified. These themes are
summarized in Table 2. Verbatim quotes demonstrating
each category are included in the Appendix (Table 4).
Theme 1: Facing challenges in health literacy
The period preceding the personal diagnosis of CRC is
characterized by health literacy challenges for both patients
and health professionals. Patient challenges include igno-
rance of one’s family history, lack of knowledge regarding
the implications of a family history of cancer, and more
specifically, ignorance of the utility of genetic assessment.
Patients perceive that these health literacy challenges are
not adequately addressed by health professionals.
Patient lack of awareness
The participants have some awareness of their family his-
tory of cancer. This knowledge however is imprecise:
specific details regarding the exact type of cancers, age at
diagnosis and exact relationship of affected relatives may
not be known.
According to participants, their knowledge is greatly
influenced by family communication style and dynamics.
In some families communication is sparse and there is
significant ignorance about health matters including cancer.
In other families there is better communication and a
greater awareness of family history of CRC.
Prior to the diagnosis of cancer, there appears to be a
clear disconnect between one’s family history of CRC and
one’s own personal health history. Participants usually do
not directly link the family history of cancer to their own
personal risk. They tend to see family history as outside
their own personal history. In fact, the family history and
personal history are often perceived as two parallel entities
rather than being more closely intertwined. Thus it is dif-
ficult for the individual to intuit a possible implication for
his/her own future health.
Challenges with health literacy extend also to partici-
pants’ knowledge concerning genetics. Myths and mis-
conceptions characterize participants’ understanding of
genetics in general and genetic aspects of cancer predis-
position. Knowledge about genetics is non-specific and
difficult to relate to personal experience. In contrast to a
participant’s knowledge of cancer, which is a familiar
reality and part of daily existence, the realm of genetics
is generally outside the tangible experience of most
participants.
The vast majority of participants first heard about the
possibility of genetic assessment when asked to participate
in the current study. When asked to share their views on
genetic assessment, some participants perceived it as syn-
onymous with psychological counselling. For others,
genetic assessment was related to unsubstantiated and
sometimes bizarre beliefs about genetics and its intended
use. In particular, for some participants, genetic assessment
was linked to its eugenic aspects, or to other questionable
uses of genetic information (for example risk stratification
in the context of insurance).
Even when genetic assessment was perceived in a
more positive way, it was usually not perceived to be of
personal benefit/utility but as a contribution to broader
scientific knowledge. Genetic assessment was also asso-
ciated by some participants with the finding of a cure for
cancer.






Median time between diagnosis and
interview (months)
5 3.5
Age range (median) 37–77 (59) 54–79 (62)
Children 11 (92 %) 4 (57 %)
Prior experience with genetic
counselling
1 (8 %) 1 (14 %)
1st degree relatives with a cancer
diagnosis
8 (66 %) 5 (71 %)
1st degree relatives deceased after
cancer diagnosis
4 (33 %) 1 (14 %)
Post-secondary education 7 (58 %) 4 (57 %)
Worries effect daily mood 5 (42 %) 4 (57 %)
Table 2 Themes identified
Theme
I Facing challenges in health literacy
II Mapping an unknown territory
III Adjusting to cancer
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Health professionals’ passivity
In the context of ignorance of family history and genetic
predisposition, participants are highly dependent on direct
recommendations of their health care providers, both for
referral to genetics services, and for specific cancer
screening recommendations. According to our research,
patients do not initiate more intensive screening because of
the lack of an absolute recommendation of their health care
provider. Unless actively encouraged by their care provider
to seek genetic assessment or to undergo colonoscopy,
participants will forego such screening based on a false
sense of reassurance introduced by the lack of a specific
recommendation.
In summary, patients were able to learn by themselves
that CRC can sometimes be an inherited condition, how-
ever, there seemed for most participants to be an almost
complete ignorance of genetic assessment. When there was
an awareness of genetic assessment, in general, such
assessment was perceived as negative. For the few partic-
ipants who perceived genetic assessment in a positive way,
the motivation was often misguided and associated with
finding of a cure or providing researchers with an enhanced
understanding of CRC causation. The combination of
patient health care literacy challenges and health care
professionals’ passivity leads to suboptimal uptake of
genetics services and screening.
Theme 2: Mapping an unknown territory
After the initial reaction to the cancer diagnosis, partici-
pants tried to make sense of what was happening to them.
That effort included trying to identify a cause for the ill-
ness. Most of the participants readily identified that life-
style factors could contribute to CRC, but most discounted
their own lifestyles as a major predicting factor. It was
easier for participants to find an answer in their family
history. As much as the personal and family history were
seen as two parallel stories, not intertwined, before the
diagnosis, after the diagnosis that same family history
became a new focus of investigation. Indeed, the diagnosis
of CRC prompted an enquiry of a new nature. Participants
started to explore more critically the genetic aspects of
their family history. This search for understanding included
reading, research and questioning of their health care
providers.
The majority of participants heard for the first time
about genetic assessment when asked to participate in the
current research. When the process and aims of genetic
assessment were described and explained, most expressed
surprise that such a possibility could exist and that the
possibility of genetic assessment had not been discussed
with them by their physician. After being made aware of
genetic assessment, participants expressed the opinion that
they could have received more information and advice
from their physician regarding genetic assessment.
Without a definite recommendation from their physi-
cian, participants were forced to make their own decision
about proceeding with genetic counselling. Often this was
not a fully informed decision, as the majority of patients
were not provided with sufficient information and most did
not have other resources to draw on such as a family
member’s previous experience or public knowledge.
Specific contexts sometimes made decision-making
more difficult. For example, some participants faced con-
flicting opinions from family members and when discour-
aged from genetic assessment, did not have enough
knowledge to be able to argue against such advice in a well
informed manner. This was particularly evident for indi-
viduals who were advised to avoid genetic assessment for
fears related to insurability and privacy.
For many participants, after the process of genetic
assessment was explained, the major motivation for
agreeing to genetic assessment was to provide information
for other family members. Participants who themselves had
children were more likely to be interested in pursuing
counselling and testing. Participants without children were
more likely to decline assessment. No participants
expressed that they were motivated to seek genetic
assessment because of potential implications for them-
selves in terms of treatment or screening for other cancers.
In the process of becoming informed about genetic
assessment, participants became much more aware of the
possibility of stigmatization and the emerging implications
for family members. Participants voiced clear concerns about
access to and potential uses of their genetic information.
In summary, patients had to map an unknown territory
related to genetic assessment. That process of mapping
consisted of information seeking, a clarification and better
understanding of their family history, and a careful con-
sideration of the impact and clinical utility of genetic
assessment on their family and on themselves.
Theme 3: Adjusting to cancer
At the time that participants were offered the possibility of
genetic assessment, most were actively engaged in the
process of coping with a new cancer diagnosis. This
included coming to terms with new physical limitations, as
well as coping with the psychological and emotional
aspects of cancer. Participants reported experiencing a
wide spectrum of emotions including fear, anxiety, sad-
ness, shock, disbelief and numbness. Participants were also
concerned about the emotional impact that their cancer
diagnosis was having on their relatives and close ones.
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For many participants the knowledge that they were
facing a severe health threat was a transformative event,
forcing the individual to confront their own mortality, to
question their identity, to redefine priorities, and to con-
struct a new sense of normality. Many participants
expressed uncertainties about their future and noted that the
way they viewed their lives had markedly changed.
In the context of such major emotional and psycholog-
ical adjustments, genetic counselling was generally not
seen as a high priority.
For some participants the physical constraints imposed
by the cancer diagnosis (fatigue, dealing with side effects,
and need to attend other medical appointments), posed
important barriers to accessing clinical genetics services.
For participants who declined genetic assessment one of
the major barriers was timing. Many patients felt that they
did not have the personal resources to face yet another
assessment/procedure. Having to set aside additional time
or having to travel to another facility for counselling rep-
resented a major challenge.
In contrast, some participants cited convenience as a
major reason that they agreed to counselling. These par-
ticipants accepted counselling when offered in conjunction
with their regular clinic appointments.
In summary, decision making regarding genetic coun-
selling and testing was made in a very difficult situation
characterized by invasive procedures, fear, uncertainty and
vulnerability. Patients were confronting fears surrounding
death and coping with the substantial physical demands
and burden of cancer. For many participants, genetic
assessment was not viewed as a high priority among many
competing demands.
Just as importantly, there was no evidence that discus-
sion of the genetic aspects was incorporated into the
algorithm of care of newly diagnosed patients, nor was the
integration of such knowledge acknowledged as one of the
adaptive tasks faced by participants in adjustment to their
diagnosis.
Discussion
The inadequacy of physician initiated screening for LS has
been well established, as has the heterogeneity in patho-
logical assessment [34]. Multiple challenges to the imple-
mentation of universal screening for LS currently exist,
including major infrastructural needs, and the recognition
that not all of the patient and societal implications have
been adequately addressed [27, 35]. Importantly, the suc-
cess of reflex testing will be highly dependent on the
acceptance of such testing by patients and their relatives,
and on their compliance with enhanced screening [24–26].
The current study has provided three novel insights into
potential reasons for patient non-engagement in pilot
studies of reflex testing. Such insights may help to shape a
framework for the successful implementation of population
based screening for LS.
First, the current research indicates, from study partici-
pants’ perceptions, a need for educational interventions to
improve health literacy for (1) The general public; (2)
Patients diagnosed with colorectal or endometrial cancer;
and (3) Primary care physicians and health care profes-
sionals providing specialized care for newly diagnosed
Table 3 Recommendations for enhancing patient engagement in clinical genetic services, including reflex testing for Lynch syndrome
(A) General public level Comprehensive education programs need to address current gaps in knowledge. Specifically the content of such
programs needs to provide more objective and exact images of clinical genetic assessment, including specific
information related to the utility of such testing in the treatment and prevention of CRC. Additionally it is
imperative that current myths and misconceptions be targeted, as these continue to represent significant barriers
preventing participation in testing.
(B) Individual CRC patient
level
Each treating facility should include in their algorithm of care an appropriate assessment of family history, criteria
for referral for genetic counselling/testing, and a discussion of genetic assessment tailored to patient need and
knowledge. The treating facility should actively facilitate the process of genetic assessment, taking into account
the context of illness, the readiness of the patient to undertake such an assessment, and the physical proximity of
genetics services to usual place of care. Rather than assuming a standard optimal time for genetic assessment, the
cancer system must adapt to the specific patient context, recognizing the low priority placed on genetic
assessment by many patients.
(C) Health care
professional level
Health care professionals need to recognize their central role in providing CRC patients with information and
specific recommendation regarding genetic counselling/testing, and in encouraging appropriate cancer screening.
Genetic considerations need to be addressed at the time of CRC diagnosis in a systematic way that is sensitive to
patient needs and priorities, and in a way that includes concrete examples of the utility of genetic assessment in
patient treatment plans and recommendations for family members. Multidisciplinary teams caring for CRC
patients should be encouraged to incorporate genetic aspects into their algorithm of care for newly diagnosed
CRC patients.
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CRC or endometrial cancer patients. These educational
interventions should address:
a. Lack of awareness regarding general genetic principles
and lack of knowledge regarding the hereditary aspects
of cancer.
b. Lack of specific knowledge related to the clinical
utility of genetic testing for LS in treatment planning
and follow-up.
c. Misinformation or lack of knowledge related to the use
of testing results and the possibilities of insurance
discrimination and lack of patient confidentiality.
Secondly, this study highlights the central importance of
health care professional recommendations regarding
genetic assessment. Without a specific discussion of the
possible benefits (and harms) of genetic assessment, CRC
patients are currently left with an impression that such
assessment is not of value and are unlikely to pursue such
assessment on their own initiative.
Thirdly, this study highlights the importance of recog-
nizing the specific patient circumstances that exist at the time
that genetic assessment is discussed, including emotional,
physical and logistical aspects. Genetic counselling should
provide compassionate individualized opportunities that are
sensitive to the patient’s circumstance and needs. The data
highlight the importance of provision of adequate psycho-
social support and flexibility in timing of genetic assessment.
Recommendations
Using these results we are able to generate recommenda-
tions targeted to three specific stakeholder groups (Table 3),
which we believe will enhance patient engagement in reflex
testing for LS.
Conclusion
The implementation of universal screening for LS has been
adopted as a 2020 developmental objective by the Office of
Public Health Genomics in the US and is currently being
considered by other countries. Successful implementation
of such programs will be highly dependent on achieving
optimal patient engagement by addressing current gaps in
health literacy, including the misconceptions related to
potential abuses of genetic information, by inclusion of
genetic assessment in the post-CRC diagnosis care map,
and by adapting current clinical genetics services practices
to the specific context of cancer care. We conclude that if
we build it (with proper infrastructure using a public health
approach), they may come, but only if the above challenges
are addressed.
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Appendix
See Table 4.
Table 4 Verbatim quotes by theme
Theme 1: Facing challenges in health literacy
(A) Patient lack of awareness
It‘s not communicated within (families), you know everyone keeps to themselves, they don‘t really talk about illness a lot. (Acceptor, male,
37 years)
Yeah, for instance, this older cousin who had a… colon operation a year or two ago, never speaks to anybody about it. He didn‘t even speak
to his own son about it. (Acceptor, male, 77 years)
I did know about it (colorectal cancer), but I never thought it would be, I thought it was mostly a male cancer. I never thought that, no, that
I‘d be affected by it. Never even gave it a thought. (Acceptor, female, 57 years)
Genetic counselling, I‘ve never heard of. I don‘t know what and why, it almost has rings of it, for me, of sort of all those great genetic
selection and those kind of issues. (Decliner, male, 58 years)
The testing then ends up getting in the hands of laboratories, drug companies. I read about a family or a group of families, I believe they
were from New Brunswick, who have a… something special about their genetic traits. They were tested and now it turns out that some
drug company owns the rights to their—well, I guess I don‘t agree with that, and so I wouldn‘t want to do anything that would have an
effect on my family. (Decliner, female, 79 years)
It’s to help, in the process of finding a cure for cancer. (Decliner, male, 54 years)
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Table 4 continued
(B) Health professionals’ passivity
And when he mentioned maybe a colonoscopy, we just sort of shrugged it off. But he never pushed it, I sort of felt that maybe if I had more
pushing I would have done it. …I rolled the dice and I ignored the fact that I should be getting a colonoscopy… (Acceptor, female,
70 years)
They said we‘ll only go up to the turn in your bowel. But in that area they found 2, 3, or 4 polyps which they removed at the time. My family
doctor always knew this; he was my principal care provider at the time. But in spite of this he didn’t seem to feel that a colonoscopy was
necessary (Acceptor,male, 77 years).
So I don‘t even know what‘s going to happen in this testing because not a shred of it‘s been explained…. you should really have the testing
explained thoroughly in the beginning because it might influence somebody‘s choice. I don‘t know if it would have influenced my choice
because I‘m here now going ahead with it. So, we‘ll see. (Acceptor, female 64 years)
Theme 2: Mapping an unknown territory
I don‘t actually think Dr. X. talked to me about that one. (Acceptor, female, 70 years)
And of course we talked to our children and nieces and nephews and nobody seemed to want to go and do it, they were afraid that it would
be harder to get their life insurance and so on and so forth so. (Acceptor, female, 64 years)
I didn‘t see a result coming out of the counselling that would be helpful to me. (Decliner, male, 58 years)
It was about family, strictly. If I had children or grandchildren, both, I would have…very likely changed my opinion about whether or not to
proceed with the counselling. (Decliner, male, 62 years)
No, it‘s not that I didn‘t want to do it (get the genetic testing), it‘s that I wanted to protect my kids. (Decliner, male, 54 years)
But that‘s not saying I would be willing to jeopardize my family….So, one of the most important factors is around privacy for your
family…- I don‘t mind being poked and prodded and blood drawn and, if it‘s any help to anybody, but do I want to involve anything with
my family? I think that decision is theirs and when they get a little older and if they run into problems, then maybe they will decide.
(Decliner, female, 79 years)
I think there‘s a family up in Saguenay or something like that, who went through genetics. They have a disease all onto themselves and
something like that. In that case, it‘s good for them to know this but it might have caused them a little bit of harm also... well it’s just what
everybody perceives them all of a sudden as, so they have to fight this sort of prejudice against them. (Acceptor,female, 57 years)
What are they going to do with it? And what‘s going to happen to it in 5 years, 10 years, 20 years? So… because there‘s nobody or no way
that you really can say, hey, I want you to burn all that. And that‘s my concern with it… I think it‘s a good thing, but maybe it‘s the use
that all this could be put to, that‘s my concern. (Decliner, female, 79 years)
Theme 3: Adjusting to cancer
If I considered it [genetic counselling] as being important, we probably would have worked on some sort of scheduling, but at that point in
time, other things were on my mind and we were already on the road to having the operation done and that would be priority, you know.
(Decliner, male, 67 years)
It wasn‘t really big on my list, I guess…. But I had to get chemo, I had to go for blood work, I didn‘t really have to do this. (Acceptor,
female, 70 years)
Mmm… I‘m sort of busy right now…with something called cancer. (Decliner, male, 62 years)
My initial reaction when it was mentioned was put it in the drawer. I‘ve got just all I want to handle right now, let me get through this.
(Decliner, female, 79 years)
Given that I got a lot on my plate, I‘m not interested. After this is over (laughs), if somebody came back to me and said, look, I understand
you‘re reasonably well, you‘re over your surgery, you don‘t have any other real problems, any other big demands in your time or energy?
No. Would you consider genetic testing because of these benefits to other people? Yeah, of course I would. (Decliner, male, 62 years)
I was going through an awful lot at that time, one more or one less didn‘t really matter. I live pretty far from the hospital so my biggest
concern is to try and get everything packed into the same day, but sometimes it‘s pretty difficult to do that. (Acceptor, female, 57 years)
Reflex testing for Lynch syndrome 81
123
visit a cancer genetics clinic. Dis Colon Rectum 51:1249–
1254
8. Alberto VO, Harocopos CJ, Patel AA, Clark SK (2006) Family
and personal history in colorectal cancer patients: what are we
missing? Colorectal Dis 8(7):612–614
9. Meisser B (2005) Psychologic impact of genetic testing for
cancer susceptibility: an update of the literature. Psycho-Oncol-
ogy 14:1060–1074
10. Codori AM, Petersen GM, Miglioretti DL et al (1999) Attitudes
towards colon cancer gene testing. Factors predicting test uptake.
Cancer Epidemiol Biomarkers Prev 8:345–353
11. Lerman C, Hughes C, Trock BJ et al (1999) Genetic testing in
families with hereditary non-polyposis colon cancer. JAMA
281(17):1618–1622
12. Atkan-Collan K, Mecklin JP, Jarvinen H et al (2000) Predictive
genetic testing for hereditary non-polyposis colon cancer. Uptake
and long-term satisfaction. Int J Cancer 89:44–50
13. Hadley DW, Jenkins J, Dimond E et al (2003) Genetic counseling
and testing in families with hereditary nonpolyposis colorectal
cancer. Arch Int Med 163:573–582
14. Claes E, Denayer L, Evers-Kiebooms G et al (2004) Predictive
testing for hereditary non-polyposis colorectal cancer: motiva-
tion, illness representations and short-term psychological impact.
Patient Educ Couns 55:265–274
15. Esplen MJ, Madlensky L, Butler K et al (2001) Motivations and
psychosocial impact of genetic testing for HNPCC. Am J Med
Genet 103:9–15
16. Ponz De Leon M, Benatti P, Di Gregorio C et al (2004) Genetic
testing among high risk individuals in families with hereditary
nonpolyposis colorectal cancer. Br J Cancer 90:882–887
17. Porteous M, Duncidey M, Appleton S et al (2003) Is it acceptable
to approach colorectal cancer patients at diagnosis to discuss
genetic testing? A pilot study. Br J Cancer 89:1400–1402
18. Esplen MJ, Madlensky L, Aronson M et al (2007) Colorectal
cancer survivors undergoing genetic testing for hereditary non-
polyposis colorectal cancer: motivational factors and psycho-
logical functioning. Clin Genet 72(5):394–401
19. Cragun D, Malo TL, Pal T et al (2012) Colorectal cancer survi-
vors’ interest in genetic testing for hereditary cancer: implications
for universal tumor screening. Genet Test Mol Biomarkers
16(6):493–499
20. EGAPP Working Group (2009) Recommendations from the
EGAPP working group: genetic testing strategies in newly
diagnosed individuals with colorectal cancer aimed at reducing
morbidity and mortality from Lynch syndrome in relatives. Genet
Med 11(1):35–41
21. Boland CR, Shike M (2010) Report from the Jerusalem workshop
on Lynch syndrome-hereditary nonpolyposis colorectal cancer.
Gastroenterology 138(7):2197
22. Beamer LC, Grant ML, Espenchied CR et al (2012) Reflex
immunohistochemistry and microsatellite instability testing of
colorectal tumors for Lynch syndrome among US cancer pro-
grams and follow-up of abnormal results. JCO 30(10):1058–1063
23. Kastrinos F, Syngal S (2012) Screening patients with colorectal
cancer for Lynch syndrome: what are we waiting for? JCO
30(10):1024–1027
24. Mvundura M, Grosse SD, Hampel H, Palomaki GE (2010) The
cost-effectiveness of genetic testing strategies for Lynch syn-
drome among newly diagnosed patients with colorectal cancer.
Genet Med 12(2):93–104
25. Ladabaum U, Wang G, Terdiman J et al (2011) Strategies to
identify Lynch syndrome among patients with colorectal cancer:
a cost-effectiveness analysis. Ann Intern Med 155:69–79
26. Resnick K, Straughn JM, Backes F et al (2009) Lynch syndrome
screening strategies among newly diagnosed endometrial cancer
patients. Obstet Gynecol 114:530–536
27. Bellcross CA, Bedrosian SR, Daniels E et al (2012) Implement-
ing screening for Lynch syndrome among patients with newly
diagnosed colorectal cancer: summary of a public health/clinical
collaborative meeting. Genet Med 14(1):152–162
28. South CD, Yearsley M, Martin E et al (2009) Immunohisto-
chemistry staining for the mismatch repair proteins in the clinical
care of patients with colorectal cancer. Genet Med 11(11):
812–817
29. Backes FJ, Mitchell E, Hampel H, Cohn D (2011) Endometrial
cancer patients and compliance with genetic counselling: room
for improvement. Gynecol Oncol 123:532–536
30. Mackey M, Gilpin C, Asmis T, Jonker D, Holwell M, Smith E,
Allanson J, Samson A, Spector N, Tomiak E (2012) Exploring
the uptake of clinical genetics services in individuals with newly
diagnosed colorectal cancer, Oral presentation at 17th Interna-
tional Conference of Cancer Nursing, September 9–13. Czech
Republic, Prague
31. Ontario physician’s guide to referral of patients with a family
history of cancer to a familial genetics clinic or cancer genetics
clinic. Ont Med Rev, Nov 2001, 24–29
32. Karlsson G (1993) Psychological qualitative research from a
phenomenological perspective. Almgvist & Wiksell Interna-
tional, Stockholm, pp 10–11
33. Samson A, Zerter B (2003) The experience of spirituality in the
psychosocial adaptation of cancer survivors. J Pastoral Care
Counsel 57(3):329–343
34. Kalloger SE, Allo G, Mulligan AM et al (2012) Use of mismatch
repair immunohistochemistry and microsatellite instability test-
ing: exploring Canadian practices. Am J Surg Pathol 36(4):
560–569
35. Hall MJ (2010) Counterpoint: implementing population genetic
screening for Lynch syndrome among newly diagnosed colorectal
cancer patients—will the ends justify the means? J Natl Compr
Canc Netw 8(5):606–611
82 E. Tomiak et al.
123
